What antiviral antibody treatment options are available for a patient exposed to Nipah virus (NiV)?

Given the high mortality rate associated with Nipah virus (NiV) and the lack of licensed vaccines, I recommend considering the use of antiviral antibodies, such as monoclonal antibodies, as a potential treatment option for individuals who have been exposed to NiV or are at high risk of exposure. Specifically, the monoclonal antibody m102.4 has shown promise in reducing the severity of NiV disease in animal models. However, it's essential to note that this treatment is still experimental and not widely available. In the absence of antiviral antibodies, supportive care, including hospitalization and close monitoring, is crucial to manage symptoms and prevent complications. Additionally, individuals who have been exposed to NiV should be isolated to prevent further transmission, and contact tracing should be initiated to identify potential cases. If antiviral antibodies are not available, other treatment options, such as ribavirin, may be considered, although their effectiveness against NiV is not well established. Ultimately, the treatment approach should be individualized based on the patient's overall health status, medical history, and the severity of their symptoms.